Table 4 Agents targeting on inflammatory cytokines in clinical trials
From: The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment
Targets | Drugs | Phase | Conditions | Sponsor | Gov identifier |
|---|---|---|---|---|---|
IL-1β | Canakinumab | 3 | Non-Small-Cell Lung | Novartis Pharmaceuticals | NCT03626545 |
IL-1β | Canakinumab | 3 | Non-Small-Cell Lung | Novartis Pharmaceuticals | NCT03631199 |
IL-1β | Canakinumab | 2 | Chronic Myelomonocytic Leukemia | M.D. Anderson Cancer Center | NCT04239157 |
IL-1β | Canakinumab | Myelodysplastic Syndrome | |||
IL-1β | Canakinumab | Recurrent Chronic Myelomonocytic Leukemia | |||
IL-1β | Canakinumab | Recurrent Myelodysplastic Syndrome | |||
IL-1β | Canakinumab | Refractory Chronic Myelomonocytic Leukemia | |||
IL-1β | Canakinumab | Refractory Myelodysplastic Syndrome | |||
IL-1β | Canakinumab | 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Action Network | NCT04581343 |
IL-1β | Canakinumab | 3 | Lung Cancer | Mario Negri Institute for Pharmacological Research | NCT05725343 |
IL-1β | Canakinumab | 2 | Non-small Cell Lung Cancer | Memorial Sloan Kettering Cancer Center | NCT04905316 |
IL-1β | Canakinumab | 3 | Non-small Cell Lung Cancer | Novartis Pharmaceuticals | NCT03447769 |
IL-1β | Canakinumab | 2 | Non-small Cell Lung Cancer | Novartis Pharmaceuticals | NCT03968419 |
IL-1β | Canakinumab | 2 | Lung Carcinoma | M.D. Anderson Cancer Center | NCT04789681 |
IL-1β | Canakinumab | 1 | Triple Negative Breast Cancer | Novartis Pharmaceuticals | NCT03742349 |
IL-1β | Canakinumab | 3 | Metastatic Pancreatic Cancer | Pancreatic Cancer Action Network | NCT04229004 |
IL-1β | Canakinumab | Metastatic Pancreatic Adenocarcinoma | |||
IL-1β | Canakinumab | 1 | Non-small Cell Lung Cancer | Novartis Pharmaceuticals | NCT03064854 |
IL-1β | Canakinumab | 2 | Melanoma | Novartis Pharmaceuticals | NCT03484923 |
IL-1β | Canakinumab | 3 | Non-small Cell Lung Cancer | Novartis Pharmaceuticals | NCT03631199 |
IL-1β | Genakumab | 1 | Malignant Solid Tumors | GeneScience Pharmaceuticals Co., Ltd | NCT05441046 |
IL-1R | Anakinra | 2 | Multiple Myeloma | Radboud University Medical Center | NCT03233776 |
IL-1R | Anakinra | 2 | Multiple Myeloma | Radboud University Medical Center | NCT04099901 |
IL-1R | Anakinra | 2 | Pancreatic Adenocarcinoma | Baylor Research Institute | NCT04926467 |
IL-1R | Anakinra | 1 | Metastatic Breast Cancer | Baylor Research Institute | NCT01802970 |
IL-1R | Anakinra | 1 | Rectal Cancer | Goethe University | NCT04942626 |
IL-1R | Anakinra | 2 | Metastatic Colorectal Cancer | Centre Georges Francois Leclerc | NCT02090101 |
IL-1R | Anakinra | 1 | Advanced Malignant Neoplasm | M.D. Anderson Cancer Center | NCT01624766 |
Metastatic Malignant Neoplasm | |||||
Recurrent Malignant Neoplasm | |||||
Refractory Malignant Neoplasm | |||||
IL-1R | Anakinra | 1 | Pancreas Cancer | Baylor Research Institute | NCT02021422 |
IL-1R | Anakinra | 2 | Multiple Myeloma and Plasma Cell Neoplasm | Mayo Clinic | NCT00635154 |
IL-1R | Anakinra | 1 | Pancreatic Adenocarcinoma | Baylor Research Institute | NCT02550327 |
IL-1R | Anakinra | 2 | Multiple Myeloma | Radboud University Medical Center | NCT03233776 |
IL-1R | Anakinra | 2 | Pancreatic Adenocarcinoma | Baylor Research Institute | NCT04926467 |
IL-1R | Anakinra | 2 | Diffuse Large B-Cell Lymphoma | Jonsson Comprehensive Cancer Center | NCT04205838 |
IL-1R | Anakinra | High Grade B-Cell Lymphoma | |||
IL-1R | Anakinra | Progressive Disease | |||
IL-1R | Anakinra | Recurrent Diffuse Large B-Cell Lymphoma | |||
IL-1R | Anakinra | 2 | B Cell ALL | Memorial Sloan Kettering Cancer Center | NCT04148430 |
IL-1R | Anakinra | B-Cell Lymphoma | |||
IL-1R | Anakinra | B-cell Non Hodgkin Lymphoma |